Compare Icl Group Ltd (ICL) vs Summit Therapeutics Inc (SMMT) Price & Performance

ICL trades at $5.00, down 0.99% over 24 hours, with a bearish technical signal. The company reported Q1 2026 earnings of $0.11 per share, beating estimates, and recently completed an $800 million senior notes offering. Revenue for 2025 was $7.15 billion with a net income margin of 3.15%, while valuation ratios show a P/E of 24.05 and P/S of 0.88. Analyst consensus is entirely hold-rated, reflecting cautious sentiment amid mixed financial trends.

The outlook for ICL is neutral with modest growth potential, supported by operational improvements and raised 2026 EBITDA guidance. Key risks include elevated raw material costs, foreign exchange headwinds, and competitive pressures in the specialty minerals sector. Investors should weigh stable cash flows against margin compression and debt levels from recent financing activities.

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.

The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.